Drug Trial Radar · NCT07702578
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Jun 18, 2026
Primary completion
Jun 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- TScan Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.
Conditions
- AML
- MDS
Interventions
TSC-101Drug
SOC + TSC-101
ControlOther
SOC alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relapse-free survival (RFS)Time frame: 3 years
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Banner Health - MD Anderson Cancer Center
Gilbert, Arizona
Honor Health Cancer Transplant Institute
Scottsdale, Arizona
City of Hope
Duarte, California
Stanford - School of Medicine
Stanford, California
University of Colorado - Anschutz Cancer Center
Aurora, Colorado
SCRI - Colorado Blood Cancer Institute
Denver, Colorado
Yale
New Haven, Connecticut
Memorial Cancer Institute
Hollywood, Florida
Moffitt Cancer Institute
Tampa, Florida
Northside Hospital
Atlanta, Georgia
University of Chicago
Chicago, Illinois
The University of Kansas Cancer Center
Kansas City, Kansas
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute - Hematology/Oncology
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai Hospital
New York, New York
Columbia University - Irving Medical Center
New York, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Research Institute - TriStar Bone Marrow Transplant (BMT)
Nashville, Tennessee
St. David's South Austin Medical Center
Austin, Texas
Baylor University Medical Center
Dallas, Texas
The University of Texas - MD Anderson Cancer Center
Houston, Texas
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.